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Abstract
The validity of the identification and classification of human cancer using antibodies to detect biomarker proteins depends
upon antibody specificity. Antibodies that bind to the tumour-suppressor protein p16INK4a are widely used for cancer
diagnosis and research. In this study we examined the specificity of four commercially available anti-p16INK4a antibodies in
four immunological applications. The antibodies H-156 and JC8 detected the same 16 kDa protein in western blot and
immunoprecipitation tests, whereas the antibody F-12 did not detect any protein in western blot analysis or capture a
protein that could be recognised by the H-156 antibody. In immunocytochemistry tests, the antibodies JC8 and H-156
detected a predominately cytoplasmic localised antigen, whose signal was depleted in p16INK4a siRNA experiments. F-12,
in contrast, detected a predominately nuclear located antigen and there was no noticeable reduction in this signal after
siRNA knockdown. Furthermore in immunohistochemistry tests, F-12 generated a different pattern of staining compared to
the JC8 and E6H4 antibodies. These results demonstrate that three out of four commercially available p16INK4a antibodies
are specific to, and indicate a mainly cytoplasmic localisation for, the p16INK4a protein. The F-12 antibody, which has been
widely used in previous studies, gave different results to the other antibodies and did not demonstrate specificity to human
p16INK4a. This work emphasizes the importance of the validation of commercial antibodies, aside to the previously
reported use, for the full verification of immunoreaction specificity.
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Introduction
For the accurate diagnosis of human cancers, protein expression
has been the focus of much attention due to the accuracy,
sensitivity and ease with which antibodies can be used to detect the
presence of proteins in tissue samples. P16INK4a, classified as an
important tumour-suppressor protein, is a potent inhibitor of cell
proliferation that mediates G1 cell cycle arrest through the
regulation of Retinoblastoma (Rb) family of proteins [1,2].
Inactivation of p16INK4a expression via point mutation, small
deletion or promoter methylation has been reported in numerous
types of human malignancies, resulting in it being extensively
studied as a biomarker for cancer diagnosis and prognosis.
Although some cancers are associated with a down-regulation of
p16INK4a [3] others, particularly those associated with human
papillomavirus infection, are associated with an increased expres-
sion. Currently, there is evidence that immunohistochemical tests
for p16INK4a expression can be a valuable supplementary marker
for cervical cancer diagnosis as p16INK4a protein is over-
expressed in most cases of cervical dysplasia and invasive
squamous cell carcinoma [4–7]. P16INK4A immunohistochemis-
try analysis of biopsy specimens has also been proposed as a
prognostic test in cases of non-small cell lung cancer [8],
differentiated thyroid cancer [9] and melanoma [10]. However,
p16INK4a as a biomarker in cancer diagnostics has been most
useful in conjunction with other biomarkers, particularly in
supporting histological test for cervical cancer [6].
For an antibody to be used in a diagnostic kit, full validation of
the antibody is essential to ensure its specificity and sensitivity to
the target protein in the appropriate assay. For example, the
specificity and sensitivity of the p16INK4a antibody E6H4 has
been validated in human samples [4] and is now used in diagnostic
kits for cervical cancer. However, most antibodies that are
commercially available for research purposes are less well
characterised.
We report the examination of four p16INK4a antibodies
recommended for detection of human p16INK4a antigen that are
either used extensively in western blot analyses (H-156), human
tissue staining (JC8), bind to a specific nuclear isoform of
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p16INK4a (F-12) or considered a gold standard in cervical
diagnostics (E6H4). The antibodies were examined by western blot
analysis, immunoprecipitation (IP), immunohistochemistry (IHC)
and immunocytochemistry (ICC) tests. Furthermore we examined
the effect of p16INK4a siRNA knockdown on immunocytochem-
istry staining.
Materials and Methods
Antibodies
Anti-p16INK4a antibodies tested were mouse monoclonal F-12
(sc-1661, Santa Cruz Biotechnology) raised against full length
p16INK4a of mouse origin, mouse monoclonal JC8 (sc-56330,
Santa Cruz Biotechnology) against human full length p16, rabbit
polyclonal H-156 (sc-759, Santa Cruz Biotechnology) against
human full length p16INK4a and mouse monoclonal antibody
clone E6H4 (CINtec Histology Kit, MTM Laboratories) raised
against human p16INK4a protein.
Western Blotting
Human embryonic kidney (Hek293) and cervix HeLa cell
lysates were used as positive controls and whole cell PC-3 extract
was used as a negative control as these cells do not express the
p16INK4a protein [11]. HeLa and Hek293 cells (both cell lines
purchased from American Type Culture Collection) were lysed in
1% Triton X-100 in PBS plus protease inhibitors cocktail (Sigma)
and protein content was determined using BCA Protein Assay Kit
(Thermo Scientific). PC3 whole cell lysate was purchased from
Santa Cruz Biotechnology. Proteins were separated on the
NuPage 4–12% bis-tris acrylamide gels (Invitrogen) in MES
Buffer (Invitrogen) and transferred onto PVDF membrane
(Invitrogen). After blocking with 2% skimmed milk powder in
0.1% Tween20/PBS (PBST), membranes were probed with
primary antibodies in blocking buffer for 2 hours. Anti-p16INK4a
antibodies H-156, JC8 and F-12 were used at the following
concentrations: 0.4 mg/ml, 1 mg/ml, 1 mg/ml respectively. Blots
were washed in PBST and incubated for 1 hour with the
appropriate anti-mouse or anti-rabbit horseradish peroxidase-
conjugated secondary antibodies (Jackson ImmunoResearch)
diluted 1:4000 in blocking buffer. Detection was via Super Signal
West Pico Chemiluminescent Substrate (Thermo Scientific).
Immunoreactive bands were visualized using ChemiDoc XRS
imaging system and Quantity One analysis software (Bio-Rad).
Immunoprecipitation
HeLa and Hek293 cell lysates containing 500 mg protein were
incubated for 1 hour with 2 mg of the F12 or JC8 antibodies in a
final volume of 1ml PBST (plus protease inhibitors cocktail). As a
negative control mouse monoclonal anti-FLAG antibody was used
in the same manner. Subsequently antibody-lysate mixtures were
added to Sheep anti-Mouse IgG Dynabeads (Invitrogen) and
incubated for 1 hour. Supernatants were collected and beads
washed 5 times with PBST. Protein-antibody complexes were
eluted from the beads by adding 70 ml of 0.1M glycine/HCl
pH 2.6. 10 ml of each IP sample was mixed with LDS buffer and
run on gels as described for Western blot analysis. Polyclonal
rabbit anti-p16INK4a H-156 antibody was used to detect
immunoprecipitated p16.
Immunocytochemistry
HeLa cells, purchased from American Type Culture Collection,
were cultured in Dulbecco’s modified Eagle medium (Invitrogen)
supplemented with 10% fetal bovine serum and 1 mM sodium
pyruvate. For ICC experiments cells were seeded at 16105 per
well on glass coverslips in 6-well plates and allowed to attach for 24
hours. Following fixation in 2% paraformaldehyde for 20 minutes,
PBS wash, and permeabilization with 0.5% saponin in PBS, cells
were blocked for 1 hour with 0.2% bovine serum albumin in PBS
and subsequently incubated with primary antibodies for two
hours. Anti-p16INK4a antibodies H-156, F-12 and JC8 were used
at the following concentrations: 1 mg/ml, 1 mg/ml and 2 mg/ml
respectively and E6H4 as received. Cells were washed four times
with 0.2% BSA in PBS and incubated for two hours with
secondary antibodies. Secondary antibodies were Alexa Fluor 488
donkey anti-rabbit, Alexa Fluor 488 donkey anti-mouse and Alexa
Fluor 633 donkey anti-sheep (Invitrogen). Cover-slips were
mounted using ProLong Gold Antifade Reagent. For confocal
microscopy a Leica TCSSP1 confocal scanning laser microscope
with Leica LCS software was used. Images were acquired using a
6361.4 n.a oil immersion objective. 488 nm and 633 nm laser
excitation wavelengths were utilised.
Immunohistochemistry
Formalin fixed paraffin embedded breast skin, diagnosis
unknown, was sourced from Source BioScience (formerly Medical
Solutions) UK, and three cervical samples (one adenocarcinoma,
one squamous cell carcinoma [SCC] and one keratinising SCC)
were sourced from TissueSolutions UK. Sections of benign nevi
were obtained from Fox Chase Cancer Center (Philadephia,
USA); nevi were designated benign after histological examination
by a pathologist. In order to detect p16INK4a in the tissues,
CINtec clinical test reagents were used according to the
manufacturers’ instructions (CINtec Histology Kit, MTM Labo-
ratories). Serial sections were treated for 1 hour with one of the
following, control no antibody solution (CINtec kit), anti-
p16INK4a antibodies: E6H4 as received (CINtec kit), F-12 at
0.4 mg/ml and JC8 at 0.4 mg/ml diluted in 2% bovine serum
albumin in TBS. Sections were counterstained with Mayer’s
hematoxylin, washed and mounted in glycergel (DAKO).
siRNA Mediated p16INK4a Knockdown
HeLa cells, purchased from American Type Culture Collection,
were transfected using 2 mg/ml lipofectamine 2000 (Invitrogen)
and 40 nM of siRNA probe 403 (Qiagen code SI02664403) or 817
(Qiagen code SI00299817) in Opti-MEM medium (Invitrogen) for
6 hours. Cells were returned to growth medium for 72 hours
before immunofluorescence analysis. Lipofectamine alone and
non-targeting siRNA AllStars (Qiagen) were used as negative
controls.
Results
To characterise anti-p16INK4a antibody specificity, we first
carried out western blot analysis. Both the rabbit polyclonal H-156
and mouse monoclonal JC8 antibodies detected a single band of
appropriate molecular mass for p16INK4a (approximately
16 kDa) in HeLa and Hek293 cell lysates. No such staining was
detected in lysate from PC-3 cells, in which expression of
p16INK4a is silenced by promoter methylation [11]. In contrast,
the F-12 antibody did not detect any band in the western blot
application (Figure 1A). The F-12 and JC8 were then tested for
their ability to immunoprecipitate native p16INK4a protein from
human HeLa and Hek293 cell lysates. As shown in Figure 1B, the
JC8 antibody was able to specifically immunoprecipitate antigens
from HeLa and from Hek293 cell lysates that were recognised by
the H-156 antibody and were approximately 16 kDa in size. F-12,
in contrast, did not bind to any antigen recognised by the H-156
polyclonal antibody in this test.
P16 Antibody Validation
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The anti-p16INK4a antibodies JC8, E6H4 and H-156 showed
very similar patterns of staining in ICC tests (Figure 1C–1E).
Although the HeLa cell staining was predominately cytoplasmic,
there was some evidence of weak nuclear staining. In contrast, the
F-12 antibody staining showed strong immunoreactivity in the
nucleus with little evidence of cytoplasmic staining (Figure 1F).
The variant antibody binding between F-12 and JC8 was also
observed using two different fixation techniques (Figure S1).
Additionally, F12 localisation to the chromosomes during the
metaphase and anaphase of cell division was observed (Figure 2).
We then used siRNA mediated gene knockdown followed by
immunofluorescence with the H-156, JC8 and F-12 antibodies; a
counter stain to the trans-Golgi network (antibody TGN46) was
also used to aid cellular localisation. As shown in Figure 3, the
intensity of staining was markedly reduced in siRNA treated cells
when assessed by the H-156 and JC8 antibody stains. In contrast,
the F-12 antibody staining demonstrated only moderate depletion
of nuclear immunoreactivity, and this was also observed in the
AllStars siRNA and Lipofectamine controls.
To determine whether the p16INK4a antibodies give similar
staining patterns in human tissue, IHC analysis of the F-12 and
JC8 antibodies was performed on serial tissue sections alongside
the antibody E6H4 (Figure 4) which is commonly used for the
identification of p16INK4a in cervical cancer tissue in IHC tests
[12]. Within human skin, melanocytes of benign nevi (moles) are
senescent due to their expression of a mutated and activated N-
RAS or BRAF oncogene [13]. Consequently, many of these cells
express p16INK4a [13]. In addition, the epidermis of skin from
elderly individuals has been demonstrated to harbour isolated
p16INK4a-positive cells [14]. The JC8 and E6H4 antibodies
generated virtually identical staining patterns in nevus samples,
whereas F-12 gave a different pattern of staining (Figure 4A). JC8
and E6H4 stained the senescent dermal nevus melanocytes, as
reported previously [13]. Nevus melanocytes were confirmed by
melanA staining (data not shown) and histologically by a qualified
dermatopathologist (author HW). Both antibodies stained weakly
in the epidermis, with some isolated positive cells, as reported
previously [13,14]. In contrast, F-12 stained relatively weakly in
the nevus melanocytes. Moreover, the ratio of diffuse epidermal to
nevus stain was higher for F12 compared to JC8 and E6H4, and
F12 also largely lacked the isolated p16INK4a-positive cells. We
also found that the F-12 gave a different pattern of staining to JC8
and E6H4 in a breast skin sample (Figure 4B) supporting the
notion that F-12 was binding to a different antigen to the other two
antibodies in the IHC tests. Finally, to determine the relevance of
using these antibodies for cervical diagnostics, we then stained
serial sections from three different cervical samples. Whilst JC-8
and E6H4 detected cervical neoplastic cells (Figure 5A and B), the
F-12 antibody only stained small numbers of cells peripheral to the
tumours (Figure 5C); for a negative control section, see Figure S2.
Discussion
The p16INK4a protein is 16 kDa in size and consists of 156
amino-acids [2]. In western blot tests presented here, the
p16INK4a antibodies JC8 and H156 detected a protein of the
expected size, whereas F-12 failed to detect any protein. In
addition, the JC8 antibody captured a 16 kDa protein that H156
was able to detect in western blot analysis, whereas with the same
protocol F-12 did not capture any protein that was recognised by
H156. The F-12 antibody was raised against the full length
p16INK4a protein from mouse. The high degree of amino acid
homology (85%) between p16INK4a in human and mouse
predicts that this antibody might be suitable for work in human
Figure 1. P16INK4A antibody validation. P16INK4A subcellular localization by immunofluorescence in HeLa cells using anti-p16INK4a antibodies
F-12 (A), H-156 (B), JC8 (C), and E6H4 (D); magnification bar = 20 mm. E. Comparison of anti-p16INK4a antibodies in Western Blot analysis using
p16INK4a positive Hek293 and HeLa whole cell lysates and p16INK4a negative PC3 cell extract (each loaded 20 mg whole protein per well). F.
Immunoprecipitation of p16INK4a using F-12 and JC8 mouse monoclonal antibodies, the FLAG mouse monoclonal antibody was used alongside as a
negative control.
doi:10.1371/journal.pone.0053313.g001
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Figure 2. The F12 antibody localisation to the chromosomes. HeLa cells were fixed and double-labelled by immunofluorescence with anti-
p16INK4a F12 antibody (green) and anti-TGN antibody (red). The F12 antibody localised to the chromosomes during the metaphase (A) and early
anaphase (B) of cell division.
doi:10.1371/journal.pone.0053313.g002
Figure 3. P16INK4A siRNA knockdown. HeLa cells were transfected with targeting siRNA duplexes 403 and 817, and non-targeting siRNA control
duplex AllStars or Lipofectamine 2000 alone. 72 hours post-knockdown cells were fixed and double-labelled with the anti-p16INK4a antibodies
(green) H-156, JC8, F-12 and with the TGN46 antibody (red) along with the appropriate secondary AlexaFluor antibodies. Images were separately
recorded in the red and green by immunofluorecsence confocal microscopy and merged. Magnification bar = 20 mm.
doi:10.1371/journal.pone.0053313.g003
P16 Antibody Validation
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tissue and three previous studies have indicated that F-12 is
capable of binding to a 16 kDa human protein in western blot
analysis [15,16,17]. However, our data indicates that the F-12
antibody, compared to the H156 and JC8 antibodies, has a greatly
reduced sensitivity for detection of a 16 kDa human protein in
western blot analysis. This is supported by comparable western
blot images for the JC-8 and F-12 antibodies presented in one of
the three previous reports [17] which illustrate a highly reduced F-
12 antibody sensitivity for detecting a 16 kDa protein.
A predominant cytoplasmic signal was found for the antibodies
H156, E6H4 and JC8 in ICC tests. In addition, the cytoplasmic
signal detected by H156 and JC8 was lost in siRNA mediated
knockdown of p16INK4a. This demonstrates that the antibodies
H-156 and JC8 have good specificity to human p16INK4a. In
contrast, the F-12 antibody had a predominately nuclear stain with
little, if any, staining in the cytoplasm of the HeLa cells. Two forms
of the human p16INK4a protein have been detected in 2D
electrophoresis experiments, with one form mainly located in the
nucleus and the other in the cytoplasm [18]. Whilst some reports
have located p16INK4a predominately to the cytoplasm of a
range of cell lines [4,19], two reports located p16INK4a
predominantly to the nucleus of the WI-38 fibroblast cell line
[3,20]. Hence, it is plausible that F-12 is binding to a nuclear form
of p16INK4a and the other antibodies to the cytoplasmic form.
This notion has also been recently proposed by Haller et al. [17]
who demonstrated that the F-12 nuclear stain had prognostic
value (albeit less than the JC8 cytoplasmic stain) in gastrointestinal
stromal tumours (GISTs). In addition, they found that loss of the
9P chromosomal region (which includes the p16INK4a locus) in
GISTs was associated with a decreased F-12 immunoreactivity,
suggestive that the F-12 antigen originates from a gene in this
region [21]. If true, it is intriguing that F-12 also localised to the
chromosomes during the metaphase and anaphase of cell division
as such a localisation for the p16INK4a protein has not been
previously reported. Most concerning, in ICC assays, staining by
F-12 was not abolished by siRNA knock down of p16INK4a,
supporting the notion that, at least under these conditions, the F-
12 staining is non-specific.
In IHC tests, the F-12 antibody gave variant binding patterns
compared to JC8 and E6H4 across different F-12 antibody lots
and in two different laboratories (Figure 4); in addition, differences
in tissue patterns between JC8 and F-12 has also been reported
elsewhere [17]. Together, these data indicate it was highly unlikely
that the differences in staining between antibodies were due to
purely methodological reasons. Although F-12 was predominately
located in the nucleus in ICC tests, this was not the case in IHC
tests indicating that F-12 was not binding to a protein isoform that
is exclusive to the nucleus in human tissues.
Taken together with the western blot data, these data indicate
that the F-12 antibody might not be binding to the human
p16INK4a protein. This raises doubt on the conclusions of a
number of studies that have used F-12 (all from Santa Cruz) to
detect the p16INK4a protein in human cancer tissues (24
manuscripts identified, Supporting Information S1). In most cases
the F-12 antibody was used to correlate the level of p16INK4a
expression in cancer with prognosis. Some authors have reported a
correlation of altered F-12 staining with worse patient outcome in
lung cancer [22], although others found no such correlation [23].
Moreover, it has been reported that p16INK4a inactivation,
assessed with F-12 antibody, was involved in development and
progression of other malignancies such as nasopharyngeal
carcinoma [24], thick melanomas [25], and adrenocortical
Figure 4. IHC analysis of nevi and breast skin samples. Serial sections of a nevi skin sample (A) and a breast skin sample (B) stained
immunohistochemically with the F-12 (left-hand column), JC8 (middle column) and E6H4 (right hand column) antibodies to enable field to field
comparison. The E6H4 and JC8 antibodies, but not the F-12 antibody, gave qualitatively very similar patterns of staining. The E6H4 and JC8 detected
numerous nevus melanocytes (brown staining) in the dermis, whereas only a fraction of these were weakly detected by F-12 (A). Whilst the JC8 and
E6H4 antibodies detected fibroblasts (arrows) in a breast sample (B) the F-12 antibody gave cytoplasmic staining in round mononuclear cells which
were undetected with the JC8 antibody (arrowheads). The breast and nevi experiments were carried out in independent laboratories using different
antibody lots/batches. Magnification bar = 100 mm.
doi:10.1371/journal.pone.0053313.g004
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tumours [26]. While we can not eliminate that this antibody did
bind to an isoform of the human p16INK4a protein in our tests or
in the previously reported studies, further investigations are
required before the reported F-12 data can be attributed with
certainty to the human p16INK4a protein. In conclusion, these
data pin-point the localisation of p16INK4a in human cells and
tissue, validates the specificity of three p16INK4a antibodies and
highlights the importance of specificity validation for commercially
available antibodies.
Supporting Information
Figure S1 ICC analysis with different fixation techniques. HeLa
cells grown on glass coverslips were fixed either with 2%
paraformaldehyde (PFA) for 20 minutes or with ice-cold
methanol-acetone (M/A) mixture (1:1) for 5 minutes and
immunofluorescently labelled with ant-p16INK4A antibodies F12
and JC8 as described in Materials and Methods. Slight differences
in antibody staining for both F12 and JC8 antibodies are seen
between different fixatives, immunofluorescent signal is more
intense in cells fixed with PFA. It is also apparent in phase-contrast
images that alcohol fixative did not preserve cell morphology as
well as paraformaldehyde. Therefore the difference in intensity of
immunolabelling can be explained as effect of morphological
changes rather than any alterations in antibody staining pattern
under different fixation methods. Moreover, with both fixatives,
the F-12 antibody shows only nuclear immunoreactivity whereas
the JC8 antibody stains nuclear and cytoplasmic antigen.
(TIF)
Figure S2 P16INK4a antibody staining of a cervical sample
including negative control. No primary antibody (left-hand image),
F-12 (second from left), JC8 (second from right) and E6H4 (right-
Figure 5. IHC analysis of cervical samples. Serial sections of three cervical SCC samples stained immunohistochemically with the F-12 (left-hand
column), JC8 (middle column) and E6H4 (right hand column) antibodies to enable field to field comparisons. F-12 failed to stain neoplastic structures
clearly detected by JC8 and E6H4 in SCC (A) and keratinising SCC (B) samples, and gave a different pattern of cellular staining in tissue peripheral to
the neoplastic mass in an adenocarcinoma cervical sample (compare arrows and arrowheads in C). Magnification bar = 100 mm. For a comparative
negative control sections, see Figure S2.
doi:10.1371/journal.pone.0053313.g005
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hand image) staining of serial sections of a cervical sample; brown
cellular staining is evident in all images but the negative control.
(TIF)
Supporting Information S1 References for the use of F12
antibody.
(DOC)
Acknowledgments
We would like to thank Barbara Strongitharm and Nikki Hudson for
technical support, John Sedivy and Andrea Maier for advice in this work.
Author Contributions
Conceived and designed the experiments: MS SW DAG WP JP PDA.
Performed the experiments: MS WP JP. Analyzed the data: MS SW DF
DAG WP JP PDA. Contributed reagents/materials/analysis tools: MS SW
DF DAG WP JP PDA HW. Wrote the paper: MS DAG WP.
References
1. Liggett WH Jr, Sirdansky D (1998) Role of the p16INK4a tumor suppressor
gene in cancer. J Clin Oncol 16(3): 1197–206.
2. Rocco JW, Sirdansky D (2001) P16INK4A (MST-1/CDKN2/INK4a) in cancer
progression. Experimental Cell Research 264: 42–55.
3. Okamoto A, Demetrick DJ, Spillare EA, Hagivara K, Hussain SP, et al. (1994)
Mutations and altered expression of p16INK4 in human cancer Proc Natl Acad
Sci USA 91: 11045–11049.
4. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, et al. (2001)
Overexpression of p16INK4A as a specific marker of dyplastic and neoplastic
epithelial cells of the cervix uteri. Int. J. Cancer 92: 276–284.
5. Volgareva G, Zavalishina L, Andreeva Y, Frank G, Krutikova E, et al. (2004)
Protein p16INK4a as a marker of dysplastic and neoplastic alterations in cervical
epithelial cells. BMC cancer 4: 58.
6. Dray M, Russell P, Dalrymple C, Wallman N, Angus G, et al. (2005)
P16(INK4a) as a complementary marker of high-grade intraepithelial lesions of
the uterine cervix. I: Experience with squamous lesions in 189 consecutive
cervical biopsies. Pathology 37(2): 112–24.
7. Cuschieri K, Wentzensen N (2008) Human papillomavirus mRNA and
p16INK4a detection as biomarkers for the improved diagnosis of cervical
neoplasia. Cancer Epidemiol Biomarkers Prev 17(10): 2536–45.
8. Zhu CQ, Shih W, Ling CH, Tsao MS (2006) Immunohistochemical markers of
prognosis in non-small cell lung cancer: a review and proposal for a multiphase
approach to marker evolution. J Clin Pathol 59(8): 790–800.
9. Melck A, Masoudi H, Griffith OL, Rajput A, Wilkins G, et al. (2007) Cell cycle
regulators show diagnostic and prognostic utility for differentiated thyroid
cancer. Ann Surg Oncol 14(12): 3403–11.
10. Gould Rotheberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO,
et al. (2009) Melanoma prognostic model using tissue microarrays and genetic
algorithms. J Clin Oncol 27(34): 5772–80.
11. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, et al. (1997)
Abrogation of the Rb/p16INK4a tumor-suppressive pathway in virtually all
pancreatic carcinomas. Cancer Res 57(15): 3126–30.
12. Wang SS, Trunk M, Schiffman M, Herrero R, Sherman ME, et al. (2004)
Validation of p16INK4a as a marker of oncogenic human papillomavirus
infection in cervical biopsies from a population-based cohort in Costa Rica.
Cancer Epidemiol Biomarkers Prev 13: 1355–1360.
13. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, et al.
(2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi.
Nature. 436(7051): 720–4.
14. Pavey S, Conroy S, Russell T, Gabrielli B (1999) Ultraviolet radiation induces
p16CDKN2A expression in human skin. Cancer Res 59: 4185–4189.
15. Marra DE, Simoncini T, Liao JK (2000) Inhibition of Vascular Smooth Muscle
Cell Proliferation by Sodium Salicylate Mediated by Upregulation of p21Waf1
and p27Kip1. Circulation 102(17): 2124–30.
16. Groeger AM, Caputi M, Esposito V, De Luca A, Bagella L, et al. (1999)
Independent prognostic role of p16INK4a expression in lung cancer. J Thorac
Cardiovasc Surg 118: 529–535.
17. Haller F, Agaimy A, Cameron S, Beyer M, Gunawan B, et al. (2010) Expression
of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms
exist that independently correlate with poor prognosis. Histopathology. 56(3):
305–318.
18. Nilsson K, Landberg G (2006) Subcellular localization, modification and protein
complex formation of the cdk-inhibitor p16INK4a in Rb-functional and Rb-
inactivated tumor cells. Int J Cancer 118: 1120–1125.
19. McKenzie HA, Fung C, Becker TM, Irvine M, Mann GJ, et al. (2010)
Predicting functional significance of cancer-associated p16(INK4a) mutations in
CDKN2A. Hum Mutat 31: 692–701.
20. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, et al. (1995)
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppres-
sor p16. Nature 375: 503–506.
21. Haller F, Lobke C, Ruschhaupt M, Cameron S, Schulten HJ, et al. (2008) Loss
of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent
cell cycle promotion in gastrointestinal stromal tumours (GISTs). J Pathol.
215(3): 253–262.
22. Cheng Y, Lee S, Harn HJ, Chen CJ, Chang YC, et al. (2003) Prognostic
prediction of the immunohistochemical expression of p53 and p16INK4a in
resected non-small cell lung cancer. Eur J Cardiothorac Surg 23: 221–228.
23. Chen J, Chen Y, Chen C, Wang Y (2001) Loss of p16INK4a and/or pRb
protein expression in NSCLC An immunohistochemical and prognostic study.
Lung Cancer 31: 163–170.
24. Lin H, Berry GJ, Sun Z, Fee WE Jr (2006) Cyclin D1 and p16INK4a expression
in recurrent nasopharyngeal carcinoma. World J Surg Oncol 7: 1–7.
25. Soares de Sa BC, Fugimori ML, Ribeiro K, Neto JP, Neves RI, et al. (2009)
Proteins involved in pRb and p53 pathways are differentially expressed in thin
and thick superficial spreading melanomas. Melanoma Research 19: 135–141.
26. Pilon C, Pistorello M, Moscon A, Altavilla G, Pagotto U, et al. (1999)
Inactivation of the p16INK4a Tumor Suppressor Gene in Adrenocortical
Tumors. J Clin Endocrinol Metab 84(8): 2776–2779.
{ Deceased.
P16 Antibody Validation
PLOS ONE | www.plosone.org 7 January 2013 | Volume 8 | Issue 1 | e53313
